Compare Eli Lilly And Co (LLY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sony Group Corp — how do they compare? Eli Lilly And Co trades at $1,219.87 (market cap $1.08T), while Sony Group Corp trades at $23.52 (market cap $138.43B). The key difference: Eli Lilly And Co is far larger — about 7.8× Sony Group Corp's market cap, and Sony Group Corp pays the higher dividend (0.67%). Which is the better fit depends on your goals.
| LLY | SONY | |
|---|---|---|
Market Cap | $1.08T | $138.43B |
Sector | Health | Technology |
52-Week High | $1.24K | $30.26 |
52-Week Low | $639.43 | $19.32 |
Enterprise Value | $1.13T | $136.35B |
Dividend Yield | 0.57% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Sony's stock is trading at $23.48, down 1.43% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong cash flow of $1.07 trillion in 2025 and beat EPS estimates in two of the last three quarters, though Q1 2026 was a miss. Recent news highlights success from Spider-Man: Brand New Day and a joint venture with TSMC for image sensors, signaling growth in entertainment and technology segments.
The investment outlook is positive, driven by analyst consensus favoring a buy rating (68.75%) and potential upside from blockbuster films and sensor innovation. Key risks include a projected net loss in 2026, competitive pressures in gaming, and currency volatility. Fundamentals show solid revenue but margin compression, requiring careful monitoring of profit trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
